SCHEMBL4390782

SCHEMBL4390782

COC(=O)c1ccc2c(Cl)cn(S(=O)(=O)c3ccc(C)cc3)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.57
PDE4B Q07343 2/20 0.57
PDE4C Q08493 2/20 0.57
PDE4D Q08499 2/20 0.57
CYP2C9 P11712 3/20 0.47
GLA P06280 1/20 0.44
ALDH1A1 P00352 2/20 0.44
TCF4 P15884 1/20 0.44
CTNNB1 P35222 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
FBP1 P09467 1/20 0.43
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
KDM4E B2RXH2 2/20 0.43
UBE2N P61088 1/20 0.43
ALOX5 P09917 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1554312 0.88 PDE4A (0.61) PDE4APDE4BPDE4CPDE4DCYP2C9
SCHEMBL5427469 0.79 MEN1 (0.49) PDE4APDE4BPDE4CPDE4DCYP2C9
SCHEMBL13302156 0.79 CYP2C9 (0.49) PDE4APDE4BPDE4CPDE4DCYP2C9
SCHEMBL1778442 0.78 CYP2C9 (0.48) PDE4APDE4BPDE4CPDE4DCYP2C9
SCHEMBL30955477 0.77 CPT1A (0.54) CYP2C9TCF4CTNNB1MEN1KMT2A
SCHEMBL9372377 0.77 CPT1A (0.54) CYP2C9TCF4CTNNB1MEN1KMT2A
SCHEMBL16053003 0.76 MEN1 (0.52) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL8601359 0.76 PDE4A (0.64) PDE4APDE4BPDE4CPDE4DL3MBTL1
SCHEMBL1156364 0.75 CYP2C9 (0.46) CYP2C9GLAALDH1A1TCF4CTNNB1
SCHEMBL16505983 0.75 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 EP disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 EP disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 WO disclosed
EP-1051176-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2000-11-15 EP disclosed
WO-2000032590-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-08 WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 PDE4A 2018/4885PDE4B 1777/4885PDE4C 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.